EA014675B1 - Способ применения антагонистов il-6 с ингибиторами протеасом - Google Patents

Способ применения антагонистов il-6 с ингибиторами протеасом Download PDF

Info

Publication number
EA014675B1
EA014675B1 EA200870029A EA200870029A EA014675B1 EA 014675 B1 EA014675 B1 EA 014675B1 EA 200870029 A EA200870029 A EA 200870029A EA 200870029 A EA200870029 A EA 200870029A EA 014675 B1 EA014675 B1 EA 014675B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
bortezomib
proteasome inhibitor
disease
fragment
Prior art date
Application number
EA200870029A
Other languages
English (en)
Russian (ru)
Other versions
EA200870029A1 (ru
Inventor
Мохамед Заки
Джеффри Немет
Роберт Орловски
Original Assignee
Сентокор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентокор, Инк. filed Critical Сентокор, Инк.
Publication of EA200870029A1 publication Critical patent/EA200870029A1/xx
Publication of EA014675B1 publication Critical patent/EA014675B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA200870029A 2005-12-09 2006-12-08 Способ применения антагонистов il-6 с ингибиторами протеасом EA014675B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74915205P 2005-12-09 2005-12-09
PCT/US2006/061786 WO2007067976A2 (en) 2005-12-09 2006-12-08 Method of using il6 antagonists with proteasome inhibitors

Publications (2)

Publication Number Publication Date
EA200870029A1 EA200870029A1 (ru) 2008-10-30
EA014675B1 true EA014675B1 (ru) 2010-12-30

Family

ID=38123650

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870029A EA014675B1 (ru) 2005-12-09 2006-12-08 Способ применения антагонистов il-6 с ингибиторами протеасом

Country Status (15)

Country Link
US (1) US20090022726A1 (https=)
EP (1) EP1954310A4 (https=)
JP (1) JP2009518447A (https=)
KR (1) KR20080072761A (https=)
CN (1) CN101325969A (https=)
AR (1) AR057227A1 (https=)
AU (1) AU2006321610A1 (https=)
BR (1) BRPI0619498A2 (https=)
CA (1) CA2632732A1 (https=)
EA (1) EA014675B1 (https=)
IL (1) IL191694A0 (https=)
NO (1) NO20082907L (https=)
TW (1) TW200803895A (https=)
WO (1) WO2007067976A2 (https=)
ZA (1) ZA200805956B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
WO2005105827A2 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US8088741B2 (en) 2004-05-10 2012-01-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
RU2453556C2 (ru) 2005-11-09 2012-06-20 Протеоликс, Инк. Соединения для ингибирования фермента
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
CA2637917C (en) 2006-01-27 2015-11-24 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
WO2008090901A1 (ja) 2007-01-23 2008-07-31 Shinshu University 慢性拒絶反応抑制剤
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
KR20170040374A (ko) 2007-10-04 2017-04-12 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
EA201170527A1 (ru) * 2008-10-01 2011-10-31 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции, включающие соединения бороновой кислоты
AU2009308516B2 (en) * 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2464666B1 (en) 2009-07-15 2018-03-21 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
AU2010278067B2 (en) * 2009-07-31 2016-10-27 Shin Maeda Cancer metastasis inhibitor
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
JP5919196B2 (ja) * 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
US20140294854A1 (en) * 2011-03-10 2014-10-02 Albert Einstein College Of Medicine Of Yeshiva University Target directed to adipocytes, methods and assays for treatment of obesity
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
KR101643041B1 (ko) * 2014-04-25 2016-07-28 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2017138008A2 (en) * 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019018410A1 (en) * 2017-07-17 2019-01-24 The General Hospital Corporation COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
US20200165608A1 (en) * 2018-11-23 2020-05-28 Florida State University Research Foundation, Inc. Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161426A1 (en) * 2003-02-04 2004-08-19 Mohit Trikha Use of IL-6 antagonists in combination with steroids to enhance apoptosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
BR9914648A (pt) * 1998-10-20 2001-11-27 Millennium Pharm Inc Processo para monitorar ação medicamentosa deinibidor de proteasoma
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161426A1 (en) * 2003-02-04 2004-08-19 Mohit Trikha Use of IL-6 antagonists in combination with steroids to enhance apoptosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BACCADORO, M. et al. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy, Cancer Cell International, 1 June 2005 (01.06.2005), Vol. 5, page 18 [online]. [Retrieved on 2007.07.12]. [Retrieved from the internet: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1164423&blobtype=pdf]. *

Also Published As

Publication number Publication date
JP2009518447A (ja) 2009-05-07
CA2632732A1 (en) 2007-06-14
IL191694A0 (en) 2008-12-29
ZA200805956B (en) 2009-10-28
EP1954310A4 (en) 2009-04-22
BRPI0619498A2 (pt) 2011-10-04
US20090022726A1 (en) 2009-01-22
EP1954310A2 (en) 2008-08-13
WO2007067976A3 (en) 2008-02-14
TW200803895A (en) 2008-01-16
AU2006321610A1 (en) 2007-06-14
KR20080072761A (ko) 2008-08-06
CN101325969A (zh) 2008-12-17
NO20082907L (no) 2008-08-26
WO2007067976A2 (en) 2007-06-14
EA200870029A1 (ru) 2008-10-30
AR057227A1 (es) 2007-11-21

Similar Documents

Publication Publication Date Title
EA014675B1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
JP7579589B2 (ja) Ｒａｎタンパク質関連神経学的疾患を処置するための方法
US20080081041A1 (en) Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
KR102460362B1 (ko) 자가면역 질환의 치료 및 예방을 위한 2-치환된 인다졸의 용도
CA2646902C (en) Cxcl13 antagonists and their use for the treatment of inflammatory diseases
KR102346566B1 (ko) 섬유성 질환의 치료 방법
JP2011256183A (ja) ニューロピリンアンタゴニスト
CN1553813A (zh) 结合至C5和C5a但不阻止C5b形成的补体途径抑制剂
JP7721142B2 (ja) Ｍａｓｐ－２阻害剤および使用方法
CN105899231A (zh) 用于在具有升高水平的tlr4配体和其它生物标记的患者中诊断和治疗病症的方法和组合物
CA2682666A1 (en) Cxcl13 antagonists and their use for the treatment of inflammatory diseases
US10183971B2 (en) SAA-domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases
CA3192306A1 (en) Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
KR101525919B1 (ko) 자가면역 질환 예방 및 치료를 위한 ｔｎｆｒ２를 기반으로 하는 이중 항체
MX2008007329A (en) Method of using il6 antagonists with proteasome inhibitors
RU2844840C1 (ru) Антитела к интерлейкину-33 и их применение
WO2025024265A1 (en) Methods of assessing citrullination and activity of pad4 modulators
WO2026020127A2 (en) Methods of assessing citrullination and activity of pad2 modulators
JP2025133077A (ja) Ｈｔｌｖ－１関連脊髄症（ｈａｍ）における形質細胞を標的とした治療又は予防剤
HK1071304B (en) Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
EA040576B1 (ru) Применение 2-замещенных индазолов для лечения и/или профилактики нарушений, опосредованных irak4

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU